La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Howmet Aerospace a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Howmet Aerospace..

Howmet Aerospace (NYSE:HWM) Azioni, Catena delle Opzioni

HOWMET AEROSPACE INC

Howmet Aerospace

Howmet Aerospace Inc produces products that are majorly used in aerospace, commercial transportation, and industrial and other markets. The company seeks to provide its customers with solutions by offering differentiated products such as airfoils with cooling and coatings for extreme temperature applications, specially designed fasteners for lightweight composite airframe construction, reduced assembly costs, lightning strike protection, and lightweight aluminum commercial wheels. It has four reportable segments namely, Engine Products, Fastening Systems, Engineered Structures, and Forged Wheels.

Shibuya,,Tokyo,,Japan,-,March,5,2022:,Exterior,Of,The

Long Ideas

Tech

Trading Ideas

PLTR

UBER

VRSN

Le azioni dell&#39;S&amp;P 500 che stanno registrando le migliori performance dell&#39;anno. Quali sono le società in forte crescita?

I migliori performer dell&#39;S&amp;P 500: ecco le azioni che stanno volando alto

Howmet Aerospace Inc

HOWA MACHINERY LTD by HOWA MACHINERY LTD.

Howmet Aerospace Inc. $3.75 Preferred Stock

News

HOND

Terrestrial Energy And HCM II Acquisition File Draft S-4 For SPAC Merger; Plan Nasdaq Listing As 'IMSR' In H2 2025

WIIM

ALLY

Ally Financial is trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Morgan Stanley analyst Toni Kaplan maintains Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Equal-Weight and raises the price target from $213 to $220.

Price Target

Analyst Ratings

CTAS

Morgan Stanley Maintains Equal-Weight on Cintas, Raises Price Target to $220

Earnings

SCHW

Schwab Trading Revenue Increased 23% YoY

Alert confirms a reversal in early weakness in TSM
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17205417/Screenshot-2025-07-17-at-4.49.28%E2%80%AFPM-1024x879.png" alt="" class="wp-image-16026" /></figure>
Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:11 AM on July 17th, a significant trading signal occurred for Taiwan Semiconductor (TSM) as it demonstrated a Power Inflow at a price of $243.05. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TSM's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TSM&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSM,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $243.05. The returns on the High price ($248.27) and Close price ($245.11) after the Power Inflow are respectively 2.1% and 0.9%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Taiwan Semi Stock Rises 2.1% After Key Trading Signal

The U.S. Food and Drug Administration&#8217;s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Blenrep <a href="https://www.benzinga.com/general/biotech">(belantamab mafodotin-blmf) combinations</a>.
The belantamab mafodotin combinations were <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-fda-advisory-committee-review-of-blenrep-belantamab-mafodotin-blmf-combinations-for-patients-with-relapsedrefractory-multiple-myeloma/" rel="noreferrer noopener">evaluated</a> in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
The FDA will consider the committee&#8217;s recommendation as it finalises its review on Blenrep ahead of the 23 July 2025 PDUFA date.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44873982/uk-becomes-first-country-to-authorize-blenrep-in-two-combo-regimens" rel="noreferrer noopener">UK Becomes First Country To Authorize Blenrep In Two Combo Regimens</a>
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.
GSK remains confident in the benefit/risk profile of Blenrep (belantamab mafodotin-blmf) and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple myeloma.
Ahead of the meeting, the FDA staff <a target="_blank" href="https://www.fda.gov/media/187578/download" rel="noreferrer noopener">released</a> a document highlighting key issues of high rates of ocular toxicity, including keratopathy (changes in the corneal epithelium) and visual acuity changes, and poor tolerability seen with each regimen and the resulting uncertainty regarding the appropriateness of the proposed dosages of belantamab mafodotin.
Despite differences in the belantamab mafodotin dosing regimens evaluated in DREAMM-7 and DREAMM-8, there were high rates of ocular toxicity in both trials.
Most patients experienced Keratopathy and Visual Acuity (KVA) events, including high-grade events (all grades: 92% and 93% and Grade 3-4: 77% and 78%, in DREAMM-7 and DREAMM-8, respectively).
The majority of patients (70% in DREAMM-7 and 72% in DREAMM-8) experienced recurrent ocular toxicity events (median of 3 Grade 2 or higher KVA events).
Over 50% of patients (58% in DREAMM-7 and 57% in DREAMM-8) had ongoing Grade 2 or higher KVA events at the data cut-off.
In both trials, there were high rates of dose modifications due to KVA events and recurrent KVA events. The majority of patients (76% in DREAMM-7 and 78% in DREAMM-8) had at least one dose modification due to a KVA event.
The document noted that the corneal toxicity seen with belantamab mafodotin is a unique risk to this product and is not seen with currently available therapies for multiple myeloma.
In May, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsedrefractory-multiple-myeloma/" rel="noreferrer noopener">recommended</a> the approval of Blenrep for adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.
An approval decision by the European Commission is expected in the third quarter of 2025.
In 2022,&nbsp;GSK withdrew&nbsp;the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial,&nbsp;which did not meet the requirements of the FDA&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">Accelerated Approval regulations</a>.&nbsp;
Price Action: At the last check Friday, GSK stock is trading lower by 1.86% to $35.79 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46487918/peter-thiel-backed-hadrian-raises-260-million-to-build-ai-powered-mega-factory-in-arizona" target="_blank" rel="noreferrer noopener">Peter Thiel-Backed Hadrian Raises $260 Million To Build AI-Powered Mega Factory In Arizona</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

Movers

General

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

Zevra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA&#xAE; (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA&#xAE; (sodium phenylbutyrate) are being presented at the 42nd Annual Meeting of the Southeastern Regional Genetics Group (SERGG), taking place July 17-19, 2025, in Asheville, North Carolina. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA is approved in the U.S. for the treatment of certain patients with urea cycle disorders (UCDs).

ZVRA

Zevra Therapeutics To Present Three Posters On MIPLYFFA And One On OLPRUVA Annual SERGG 2025

LITM

Snow Lake Begins Drilling At U.S. And Namibia Uranium Sites Amid Surge In Nuclear Demand, Eyes Maiden Resource By Year-End

Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $428 to $316.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Morgan Stanley Maintains Overweight on Elevance Health, Lowers Price Target to $316

Schwab Total Client Assets Increased 14% YoY

Morgan Stanley analyst Dara Mohsenian maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Equal-Weight and raises the price target from $153 to $165.

Morgan Stanley Maintains Equal-Weight on PepsiCo, Raises Price Target to $165

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $1.07 by 6.05 percent. This is a 56.16 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $5.851 billion which beat the analyst consensus estimate of $5.651 billion by 3.54 percent. This is a 24.75 percent increase over sales of $4.690 billion the same period last year.

Earnings Beats

Charles Schwab Q2 Adj. EPS $1.14 Beats $1.07 Estimate, Sales $5.851B Beat $5.651B Estimate

Morgan Stanley analyst Benjamin Swinburne maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1450 to $1500.

NFLX

Morgan Stanley Maintains Overweight on Netflix, Raises Price Target to $1500

Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.80 by 23.9 percent. This is a 2.06 percent increase over earnings of $0.97 per share from the same period last year. The company reported quarterly sales of $2.064 billion which beat the analyst consensus estimate of $2.039 billion by 1.24 percent. This is a 1.08 percent increase over sales of $2.042 billion the same period last year.

Ally Financial Q2 Adj. EPS $0.99 Beats $0.80 Estimate, Sales $2.064B Beat $2.039B Estimate

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) with a Market Perform and raises the price target from $61 to $63.

GSBC

Keefe, Bruyette & Woods Maintains Market Perform on Great Southern Bancorp, Raises Price Target to $63

<a href="https://www.benzinga.com/money/what-is-ethereum-etf">Spot Ethereum ETFs</a> recorded a net inflow of $602 million on July 17, marking the second-highest single-day inflow in history.
The inflow surpassed that of Bitcoin spot ETFs, which saw $523 million in net inflows on the same day, their 11th consecutive day of positive flow, according to <a href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue.
Combined, U.S. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) spot ETFs have amassed $54.3 billion and $7.09 billion in cumulative net inflows, respectively.
What Happened: The surge in investor appetite comes amid renewed market optimism, robust macroeconomic indicators, and mounting regulatory clarity, themes echoed across institutional research from Glassnode and Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
The dramatic capital rotation into ETH products aligns with a broader shift noted by analysts. "BTC is participating, but this rally belongs to ETH," said Dr. Sean Dawson, Head of Research at Derive.xyz. "The technical setup, option flows, and liquidations all point to a meaningful structural shift in positioning."
Ethereum ETFs also led in total value traded on July 17, reaching $2.29 billion, compared to Bitcoin's $3.7 billion, as tracked across major issuers like BlackRock, Grayscale, Fidelity, and Ark Invest. 
Notably, BlackRock&#8217;s Ethereum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) recorded the largest daily net inflow of $546.7 million and holds over $8.4 billion in net assets.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46463794/1-5-billion-in-one-day-why-bitcoin-and-ethereum-etfs-are-running-wild">$1.5 Billion In One Day: Why Bitcoin And Ethereum ETFs Are Running Wild</a>
From a macro and on-chain lens, the report by Coinbase and Glassnode highlights that Ethereum's liquid supply rose 8% in Q2, while illiquid supply — coins held for over a year — declined by 6%. 
Concurrently, ETH's MVRV (Market Value to Realized Value) ratio swung from negative in Q1 to positive in Q2, confirming improving profitability among holders. 
The share of ETH in profit rose from under 40% to nearly 90% during the quarter.
"With macro tailwinds, falling rates, and ETF momentum aligning, the back half of 2025 is setting up to be Ethereum's strongest in years," Dr. Dawson added.
Bitcoin, meanwhile, maintained strong institutional demand. 
As noted in the Glassnode report, U.S. spot Bitcoin ETFs purchased over 225% of all newly mined BTC since January 2024, reflecting relentless buying pressure against a structurally constrained supply.
What&#8217;s Next: While Bitcoin&#8217;s ETF net assets remain dominant at $154.6 billion, Ethereum's growing share is being closely watched.
Ethereum spot ETFs now represent 4.19% of total ETH market cap, compared to 6.51% for Bitcoin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/07/46452094/trump-wishes-bitcoin-ethereum-xrp-happy-crypto-week-it-is-all-part-of-make-america-great-again">Trump Wishes Bitcoin, Ethereum, XRP &#8216;Happy Crypto Week!&#8217; — &#8216;It Is All Part Of Make America Great Again&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

COIN

ETHA

Another $1.1 Billion: Is This Bitcoin, Ethereum ETF Buying Spree Sustainable?

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) with a Outperform and raises the price target from $48 to $50.

Keefe, Bruyette & Woods Maintains Outperform on OFG Bancorp, Raises Price Target to $50

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Outperform and raises the price target from $304 to $316.

Keefe, Bruyette & Woods Maintains Outperform on Travelers Companies, Raises Price Target to $316

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Unity Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNTY#NASDAQ">UNTY</a>) with a Outperform and raises the price target from $55 to $63.

UNTY

Keefe, Bruyette & Woods Maintains Outperform on Unity Bancorp, Raises Price Target to $63

The U.S. dollar's status as the world's premier currency could be at risk if the Federal Reserve intervenes in the bond market to curb rising interest rates, warns Fidelity's Jurrien Timmer.
What Happened: With the soaring U.S. debt, Timmer's analysis, shared on X, suggests that the Fed&#8217;s interference in the bond markets might erode the dollar's &#8220;supremacy.&#8221; This alludes to the USD&#8217;s edge as the global reserve currency.
Timmer's post highlighted the debt crisis, noting the rise in federal debt since March 2020, driven by COVID-era spending and a recent debt ceiling hike.
He warned of a potential "unsustainable debt spiral" if the term premium rises, forcing the Fed to suppress rates.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With the debt ceiling now passed, the debt is rising again and the jaws between what the Treasury is selling and what the Fed is buying continue to widen. This will only last for so long, in my view. We are now in round two of fiscal dominance, with the first $5 trillion… <a href="https://t.co/obAJzpIbYo">pic.twitter.com/obAJzpIbYo</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1945842189189472301?ref_src=twsrc%5Etfw">July 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a following post, he escalated the concern that "If the Fed is forced back into the bond market to hold down nominal and real rates, the dollar may well lose more of its supremacy premium." This interference, he argued, could weaken the dollar despite the Fed's hawkish stance.
The linkage lies in market dynamics: Fed bond purchases increase the money supply, devaluing the currency.
Timmer cited Japan's experience, where the yen fell against the dollar between 2011 and 2014, explaining that it is usually the currency that takes a hit in the presence of unsustainable fiscal policies.
"Currencies are the release valve for unsustainable fiscal policy, as Japan found out a few years ago." A weaker dollar could ease U.S. debt burdens by boosting exports, but it risks undermining global confidence.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If the Fed is forced back into the bond market to hold down nominal and real rates, the dollar may well lose more of its supremacy premium. Currencies are the release valve for unsustainable fiscal policy, as Japan found out a few years ago. The same is now true for the dollar,… <a href="https://t.co/tazvTBkF93">pic.twitter.com/tazvTBkF93</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1945845887042998546?ref_src=twsrc%5Etfw">July 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46487109/ripple-ceo-hails-genius-act-as-transformational-legislation-compares-it-to-dodd-frank-act-this-moment-is-a-historic-one">Ripple CEO Hails GENIUS Act As &#8216;Transformational Legislation,&#8217; Compares It To Dodd-Frank Act: &#8216;This Moment Is A Historic One&#8217;</a>
Why It Matters: While these factors could rob the dollar of its reserve currency status, the members of the Donald Trump administration also intend to devalue the currency.
Chatham House expert David Lubin, in a note from April, explained that the &#8220;<a href="https://www.benzinga.com/government/regulations/25/04/44858165/policy-push-vs-market-pull-dollar-under-pressure-as-reserve-currency-may-be-called-into-question-amid-tariff-turmoil">policy push</a>&#8221; from Trump‘s administration aims to weaken the dollar permanently against other currencies, hoping to reduce the trade deficit and attract manufacturers to the U.S. 
However, Lubin strongly cautioned against this approach, arguing that &#8220;if the international monetary system cannot rely on the dollar's full convertibility, or its availability in a crisis, it is entering unknown territory.&#8221;
&#8220;Undermining the dollar's global status would not only transmit huge amounts of additional uncertainty to the global economy, but would be a needless act of self-harm for the U.S.,&#8221; he added.
Price Action: The Dollar Index was down 9.33% on a year-to-date basis, where it was 0.34% lower at the 98.3970 level as of the publication of this article.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were slightly higher in premarket on Friday. The SPY was up 0.14% at $628.95, while the QQQ advanced 0.13% to $562.55, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46463595/dan-ives-picks-5-stocks-for-2nd-half-of-2025-nvidia-palantir-microsoft-and-more-golden-age-of-tech-is-here-with-ai-revolution" target="_blank" rel="noreferrer noopener">Dan Ives Picks 5 Stocks For 2nd Half Of 2025: Nvidia, Palantir, Microsoft And More: ‘Golden Age Of Tech Is Here With AI Revolution'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Comments

Howmet Aerospace

Howmet Aerospace (HWM) Opzioni

Howmet Aerospace (NYSE:HWM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO